Cancer-specific DNA repair defects are abundant in malignant tissue and present an
opportunity to capitalize on these aberrations for therapeutic benefit. Early preclinical data …

Poly (ADP-ribose) polymerase-1 (PARP-1) is a critical DNA repair enzyme in the base
excision repair pathway. Inhibitors of this enzyme comprise a new type of anticancer drug …

Esophageal adenocarcinoma (EAC) has a poor outcome, and targeted therapy trials have
thus far been disappointing owing to a lack of robust stratification methods. Whole-genome …

Poly (ADP-ribose) polymerase inhibitors (PARPis) are clinically effective predominantly for
BRCA-mutant tumors. We introduce a mechanism-based strategy to enhance PARPi efficacy …

Introduction: Despite advances in surgery and chemotherapy for ovarian cancer, 70% of
women still succumb to the disease. Biomarkers have contributed to the management of …

A synthetic lethal relationship exists between disruption of polymerase theta (Polθ), and loss
of either 53BP1 or homologous recombination (HR) proteins, including BRCA1; however …

Purpose To determine the potential for detection of incidental germline cancer
predisposition mutations through cell-free DNA (cfDNA) analyses in patients who underwent …

Inhibitors of poly (ADP-ribose) polymerases (PARPs), which play a key role in DNA
damage/repair pathways, have been developed as antitumor agents based on the concept …

Abstract Purpose: Both PARP inhibitors (PARPi) and sacituzumab govitecan (IMMU-132)
are currently under clinical evaluation in triple-negative breast cancer (TNBC). We sought to …

Background Biliary tract malignancies, in particular cholangiocarcinomas (CCA), are rare
tumors that carry a poor prognosis. BRCA2 mutation carriers have an increased risk of …